Medscape - Dr. Mary Sano: “New Data on Long-Term Safety With Bapineuzumab in Alzheimer’s Disease”

New York, NY
 – July 29, 2011 /Press Release/  –– 

Two new reports provide additional information on the safety of bapineuzumab, a humanized monoclonal antibody being developed for the treatment of Alzheimer's disease. Mary Sano, MD, PhD, professor of psychiatry at Mount Sinai School of Medicine in New York City, pointed out that the imaging abnormalities are apparent in many clinical trials investigating agents that clear amyloid. "I think it's important that we take time to understand what they mean," said Dr. Sano. "We've been offered a theory of how that abnormality may be demonstrating that an agent is actually working, so I think that's very important.” Learn more